Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 1:49 PM
Ignite Modification Date:
2025-12-24 @ 1:49 PM
NCT ID:
NCT06652295
Eligibility Criteria:
* Being 18 years of age or older
* Having stage 1-3 lymphedema according to the International Society of Lymphology (ISL) classification
* Having a diagnosis of unilateral breast cancer-related lymphedema (Doppler, lymphoscintigraphy, and computed tomography were preferred to confirm the diagnosis of lymphedema based on a comprehensive medical assessment and condition of the patient)
* No evidence/suspicion of cancer recurrence after completion of adjuvant local and systemic therapies for at least 12 months
* Not having received a complex decongestive physiotherapy programme in the last 6 months
* Volunteer to participate in the study Able to read and understand Turkish.
Exclusion Criteria:
* Inability to understand the questionnaires and refusal to participate
* History of congenital lymphedema or bilateral upper extremity lymphedema or malignant lymphedema
* Presence of neurological or mental illness or axillary web syndrome, major organ failure, or/ iatrogenic disease that may adversely affect the severity of lymphedema (such as using steroids, nonsteroidal anti-inflammatory drugs, and calcium channel blockers)
* Presence of conditions contraindicated for complex decongestive physiotherapy (active infection, deep vein thrombosis/thrombophlebitis, cardiac oedema, pulmonary disease, peripheral arterial disease, any skin disease such as scleroderma, allergic reactions to treatment).
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
65 Years
Study:
NCT06652295
Study Brief:
Protocol Section:
NCT06652295